Accelerating Commercialization in
Nanobiotechnology
SRTTD
July 30, 2010
Brooks Adams
Executive Director & President
Outline
1. COIN
2. The opportunity
3. COIN’s role
4. Working together
COIN
We promote innovation & commercialization in
nanobiotechnology & nanomedicine to enable
future economic growth & improve human life.
Key facts








Nonprofit 501c3 launched June 2009
$2.6 million funds committed
4 full-time staff
Outsource finance, marketing, & IT
University intern program (4 - 5)
8 Board members & 6 on SAB
Annual operating budget ~ $800K to 1MM
Based in Triangle; frequently in Triad & Charlotte and
beyond
The opportunity
“Human health has always been determined on the
nanometer scale…where the structure & properties of the
machines of life work in every one of the cells in every
living thing. The practical impact of nanosciences on
human health will be huge.”
Dr. Richard Smalley, Nobel Laureate
Nanobiotechnology


Application of nanotechnology materials, tools, &
processes in the life sciences & medicine:
Commercial applications:




Therapeutics & diagnostics
Medical technology & devices
Medical/life science research
Non human health-care related
Versatile structure of carbon nanotubes enables
use for variety of tasks in the body
The promise & challenge




Nanotech is a tool box not an industry
Many potential high value applications
Nanotech centers are forming globally & industry
clusters grow around them
Requisite capabilities/resources:


Research, infrastructure, talent, money, & a conducive business
environment are needed
A few major centers will develop
“A Roadmap for Nanotechnology in NC’s 21st Century Economy,” March 2006
Nanobiotech global market


2009 nanomedicine healthcare market largest in N America
at $4.75 billion followed by Europe at $3.65 billion
Nano-enabled drug delivery largest segment with expected
CAGR of 21.7% to ~ $16 billion by 2014




Biocompatible implants & coatings and diagnostics estimated
growth of 42% & 21.8%, respectively through 2014
Global clusters: US, Singapore, Canada, Australia,
Germany, China, UK, & Israel
US hubs: Boston, San Francisco, Houston, & RTP
US academic centers of excellence: NC, Mass., California,
Ohio, & Texas
Sources: Business Insights (Jan 2010), Pew Charitable Trusts, COIN database
Nanomedicine patents
3% 3%
8%
Active Implants
14%
Drugs and Therapies
Biomaterials
Imaging
57%
In vitro Diagnostics
15%
Drug Delivery
.
Provided by Wake Forest Univ. Center for Translational Nanomedicine
Site-specific, targeted delivery
Kam Leong, Duke University
Tissue engineering
Kam Leong, Duke University
Vision for NC

Assets to succeed lie in Charlotte, Triad, & Triangle


Mix of nanotech research activity, medical centers, related large/emerging
companies, and investors
To be nationally competitive, must promote projects in this corridor
leveraging resident assets
NC nanobiotech ecosystem overview


Building from thriving, mature biotech industry & infrastructure,
emerging nanobiotech sector is gaining rapid traction
NC strong in 3 of highest-growth nanotech sectors:




NC repeatedly recognized as leader in nanotech



Medicine & healthcare
Tools/instruments
Materials
2009 survey (PEN) ranked NC 8th in US & Raleigh metro area 4th
2009 US University Report & Rankings by Small Times placed NCSU 3rd
in for nanotech commercialization and UNC-CH 5th & NCSU 10th for
nanotech research
Positive political-business climate in support of biotech, low-cost of
doing business, & high quality of life

NC Innovation Council
NC nanobiotech ecosystem overview

Industry

> 70 nanotech companies & 35 nanobiotech companies


University & college resources




30 university research centers
Two nanotech PhD programs (only 36 in world)
Among 1st in nation to offer nanotech associates degree
Supportive infrastructure









> 280 US nanobiotech companies & additional 150 int’l nanobiotech companies
7 major research parks across NC
3 major nonprofit research institutes
108 medical products CRO’s
Active, engaged VC & angel investment
NC Department of Commerce
NC Biotechnology Center
Centers of Innovation: COIN, ibiliti (med tech), Drug Discovery COI
NC Regional Partnerships
Community resources


CED
SBTDC
NC among nano-enabled drug delivery research
university leaders
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
University Texas
Harvard University
MIT
University of Michigan
Johns Hopkins University
University of Illinois
Northwestern University
University of Washington
Purdue University
University of Utah
Georgia Institute of Technology
14.
Washington University
University of Florida
University Pennsylvania
15.
Cornell University
12.
13.
16.
17.
18.
19.
20.
21.
22.
Rice University
Ohio State University
25.
University of California at Los
Angeles
University of California at Santa
Barbara
University Nebraska
26.
University of North Carolina
27.
University of Wisconsin
28.
Penn State University
29.
Massachusetts General Hospital
30.
University of Kentucky
31.
Stanford University
32.
University of Maryland
33.
University of Southern California
34.
University of Pittsburgh
23.
24.
University of California at Berkeley 35.
36.
University of Massachusetts
University of California at Davis
University of California at San
Francisco
University of Minnesota
NCI
37.
SUNY Buffalo
38.
University of California at San Diego
39.
Northeastern University
40.
Carnegie Mellon University
41.
North Carolina State University
42.
Vanderbilt University
43.
Case Western Reserve University
44.
Duke University
45.
Brown University
46.
CALTECH
47.
Arizona State University
48.
Columbia University
49.
Rutgers State University
50.
University of Delaware
Emory University
Source: COIN study (based on
publications)
Leading NC nanobio companies




Liquidia: Series B VC funding, entering clinical trials
XinRay: Major partnership with Siemens
Pioneer Surgical Orthobiologics: Product on market
Biodelivery Sciences: Publicly traded;
$56.69 MM market cap
COIN’s role
COIN will help transform ideas into commercial
value.
Idea
Develop
Demo
Quality
Concept
$
Plan
Design
Test
Launch
$
Burgeoning field with challenges






Shortage of qualified personnel
Education of workforce for future
Limited funding for early-stage innovation
Lack of pre-clinical/clinical testing guidance & facilities
Development of GMP capabilities / manufacturing scale
up
Need for more:
Low-cost, flexible research space
 Multidisciplinary research partnerships
 Business development connections

COIN offers
Innovators & entrepreneurs
Resources to build relationships crucial for technology
translation & business development
Industry partners
Single point of entry to nanobiotech sectors in NC and
access to innovators & entrepreneurs
Service providers
Resources to develop nanobiotech project pipeline
COIN goals
BUILD a community of practice of NC nanobiotech
innovators & industry players focused on commercialization
CONNECT innovators with promising nanobiotechnology with industry
partners, resources, & collaborators
GROW nanobiotech infrastructure in NC
DRIVE new product development by reducing barriers to
commercialization
INCREASE the profile of NC nanobiotech activity globally
COIN programs
Events & seminars to build, connect, & inform the community:
 Nanobiotech Executive Roundtable
 Annual NC Nanotech Commercialization Conference:
Nanobio track
Membership services including knowledge-rich web portal:
 Business intelligence
 RFP scouting service
Innovation services that address specific obstacles to commercialization:

Grant writing

Incubation partners

Connections for pre-clinical testing
NC resources for pre-clinical testing
synthesis
• WFU Nanotech Center
• Nanotech Labs (Yadkinville, NC)
Characte • WFU Nanotech Center, JSNN, Forsyth Tech, Murdoch
rization
In Vitro
In Vivo
Clinical
Trials
• Murdoch, Biomedical Innovation Network, JSNN, ECU, RTI
• Murdoch, Biomedical Innovation Network, JSNN, UNC . RTI
• Duke, UNC, WFU , ECU med schools
• RTI, CROs
COIN clients & collaborators




University researchers &
tech transfer offices
Pharma/biotech,
specialty pharma, drug
delivery companies
Startups
VC, angel, & public
funding sources





Equipment & software
companies
National nanobiotech
research institutes
Trade groups
Law & accounting firms
Economic development
& policy makers
Working together
“…to increase its share of nanotechnology activity
nationally and internationally, the (Southeast) region
needs to take specific steps in achieving a leadership
role…with a focus on improved collaborations and
increasing the number and growth of nanotechnology
companies.”
Source: “Connecting the Dots,” 2006, Southern Growth Policies Board, Georgia Tech, Oak Ridge
Nat’l Lab
Creating a Southern nanotechnology strategy

Establish Southern Nanotech Network, a membership network to increase awareness of industry
among South’s citizens, governments, & businesses and:






Establish Southern Nanotechnology Institute, based on resources of Oak Ridge & others to:





Offer opportunities for collaborative interaction between the public and private sectors
Identify policy advocates
Have each Southern Growth state put advancement of nanotech as a primary economic development goals
Develop/execute branding strategy for Southern nanotech to promote South’s assets within region, nationally &
internationally
Coordinate collaborative trips to CA, NY, and MA to promote linkages between region & other major centers
Develop nanotech business incubation capacity for all Southern states
Increase funding opportunities for Southern institutions including state matching funds for SBIR and other federal
grants with specific focus and development of equity funds for nanotech companies
Enhance availability & affordability of research tools
Develop survey of nano-equipment in region’s universities & research labs, so other users may gain access &
subsidize their expenses through user agreements
Other considerations


More in-depth look at commercialization including development process, South’s market niches, & role of various
funding sources
Explore opportunity/need for equipment cooperatives with vendors
Source: “Connecting the Dots,” 2006, Southern Growth Policies Board, Georgia Tech, Oak Ridge Nat’l Lab
Summary


Technology knows no borders
Together we can accelerate commercialization in
nanobiotechnology:


Foster nano-size solutions for life science research &
medicine for the benefit of mankind
Bridge research community with business & funding
sources to create R&D collaborations, new companies,
and products
BROOKS ADAMS
Executive Director & President
brooks.adams@nc-coin.org
Cell: 804-363-9574
Assistant: Clare Valcore / 919-782-1991, Ext. 302
1
Addendum
Major categories of nanomaterials
Type
Solid nanoparticles
Definition
Ultrafine solid particles on
nanoscale, including crystals &
nanopowders
Hollow nanoparticle
Hollow nanoscale particles,
including nanotubes & other
kinds such as nanohorns &
nanocapsules
Coatings with thickness &/or
internal structures measured
in units of 100 nm or less
Bulk solids that have
macroscale external
dimensions but nanoscale
internal structure (could be
metal or alloys)
Mixture of 2 or more dissimilar
components, at least one of
which has nanoscale
dimensions
Nanoscale thin film
coatings
Nano structured
monolithic
Nanocomposites
Source: BCC research
Example
Synthetic bone made from
calcium & phosphate
particles manipulated at
molecular level
Drug delivery systems or
bundle & detonate for
cancer detection
Antimicrobial coatings
applied to surgical dressing
or medical devices
High strength medical
implants using
nanostructured pure
titanium
Devices with increased
responsiveness to pressure
for MIS techniques
Major categories of nanomaterials

Nanotools:
Device enabling viewing/manipulation of nanoscale objects
 E.g., scanning probe microscope on market today


Nanodevices
Nanomachines to do useful work in medicine
 E.g., nanorobots injected into blood to destroy cancer cells;
medical nanosensors incorporating nanoengineered
structures, e.g., spintronic sensors that incorporate nanoscale
thin films or next generation nanomedical sensors, e.g.,
respiratory gas sensors (going soon to market)

Source: BCC research